Observational analysis shows alterations in inflammatory biomarkers in MDD patients treated with omega-3 fatty acids, suggesting a potential for personalized treatment.
Key Points
Treatment with omega-3 fatty acids led to a significant reduction in depression symptoms in MDD patients, enhancing their response.
Baseline inflammatory biomarkers showed significant differences between responders and non-responders, highlighting their role in predicting treatment efficacy.
Ninety-four patients with MDD were treated with omega-3 fatty acids for 8 weeks, demonstrating effects on biomarkers related to neurotrophy.
These findings suggest the potential for personalized antidepressant strategies and enhance understanding of omega-3 fatty acids' mechanisms.